β-Amyloid Prions and the Pathobiology of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease in humans and will pose a considerable challenge to healthcare systems in the coming years.Aggregation of the b-amyloid (Ab) peptide within the brain is thought to be an initiating event in AD pathogenesis.Many recent studies in transgenic mice have provided evidence that Ab aggregates become self-propagating during disease, leading to a cascade of protein aggregation in the brain, which may underlie the progressive nature of AD.The ability to self-propagate and the existence of distinct "strains" reveals that Ab aggregates exhibit many properties indistinguishable from those of prions composed of PrP Sc proteins.Here, we review the evidence that Ab can become a prion during disease and discuss how Ab prions may be important for understanding the pathobiology of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 2×
“2012); and (5) mutations in the genes encoding the presenilin proteins increase the relative abundance of pro-amyloidogenic Aβ isoforms and cause early-onset AD (Sherrington et al. 1995).”
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 2×
“In contrast, mutations in the gene encoding tau result in the production of NFTs in the brain (Hutton et al. 1998; Spillantini et al. 1998), but not amyloid plaques.”
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 3×
“Induced Aβ prions also appear to “spread” away from the original site of inoculation (Eisele et al. 2009; Ye et al. 2015b), providing a potential molecular explanation for the progression of Aβ pathology observed in AD patients (Thal et al. 2002).”
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Indeed, Tg(AD) mice have been used to demonstrate that reducing levels of Aβ aggregates in the brain, either by vaccination or passive immunotherapy, can rescue cognitive deficits (Schenk et al. 1999; Bard et al. 2000; Janus et al.”
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 2×
“Cleavage of C99 by γsecretase is heterogeneous in nature and results in the generation of Aβ peptides varying in length from 37 to 43 amino acids (Benilova et al. 2012).”
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 4×
“…gene encoding APP cause early-onset forms of AD and increase the production of Aβ or enhance its aggregation potential (Chartier-Harlin et al. 1991; Citron et al. 1992); (2) duplication of the APP coding locus results in early-onset AD (Rovelet-Lecrux et al. 2006); (3) in Down’s syndrome…”
InfluentialA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 2×
“…pathological changes in the brain (Wisniewski et al. 1985); (4) mutations in the APP gene that decrease Aβ production are protective against AD (Jonsson et al. 2012); and (5) mutations in the genes encoding the presenilin proteins increase the relative abundance of pro-amyloidogenic Aβ…”
Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils
Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W.-M., Mattson, M. P., & Tycko, R. (2005) · Science · doi:10.1126/science.1105850 · Cited by 1,687
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 2×
“For example, Tg2576 mice expressing human APP containing the Swedish mutation (K670N/M671L) (Citron et al. 1992; Mullan et al. 1992), which causes enhanced cleavage of APP by β-secretase (Haass et al.”
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 2×
“In contrast, mutations in the gene encoding tau result in the production of NFTs in the brain (Hutton et al. 1998; Spillantini et al. 1998), but not amyloid plaques.”
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · cited 1×
“Indeed, Tg(AD) mice have been used to demonstrate that reducing levels of Aβ aggregates in the brain, either by vaccination or passive immunotherapy, can rescue cognitive deficits (Schenk et al. 1999; Bard et al. 2000; Janus et al. 2000).”
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 2×
“2010) mutations develop typical age-dependent Aβ pathology and memory deficits (Saito et al. 2014).”
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 4×
“Using a conformational stability assay that measures the relative resistance of Aβ aggregates to chemical denaturation, it was shown that the Aβ aggregates from an AD patient with the Swedish mutation in APP can be distinguished from those in an AD patient with the Arctic mutation (E693G) (Nilsberth et al. 2001) in AP…”
InfluentialOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“…in Down’s syndrome patients, an extra copy of chromosome 21, which contains the APP gene, invariably causes AD-like pathological changes in the brain (Wisniewski et al. 1985); (4) mutations in the APP gene that decrease Aβ production are protective against AD (Jonsson et al. 2012); and (5)…”
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 4×
“…plaques contained a higher ratio of Aβ42/Aβ40 peptides than the plaques in mice inoculated with Aβ42 fibrils produced in the presence of SDS. Distinct strains (or “morphotypes”) of Aβ prions have also been observed between two different lines of Tg(AD) mice, APP23 and APPPS1 (Radde et al. 2006).”
InfluentialExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 3×
“…PrP prions Aβ prions Reference(s) for Aβ Induction of protein aggregation in Tg mice expressing mutant precursor protein Yes Yes (Kane et al. 2000; Meyer-Luehmann et al. 2006) Induction of protein aggregation in Tg mice expressing wild-type precursor protein Yes Yes (Morales et al.…”
InfluentialChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 2×
“1994), develop amyloid plaques at around 3–4 months of age (Chishti et al. 2001).”
Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592 · cited 2×
“1992), which causes enhanced cleavage of APP by β-secretase (Haass et al. 1995) and, consequently, increased Aβ production, develop Aβ plaques in their brains beginning around 12 months of age (Hsiao et al.”
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., Launchbury, F., Linehan, J., Richard-Loendt, A., Walker, A. S., et al. (2015) · Nature · doi:10.1038/nature15369 · Cited by 518 · cited 2×
“2013), it has recently been shown that the brains of growth hormone recipients who died of CJD contain much higher levels of Aβ deposition than would be expected (Jaunmuktane et al. 2015).”
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401 · cited 2×
“However, current Tg(AD) mice do not constitute an ideal animal model of AD because, unlike AD patients, Tg(AD) mice do not develop NFTs in their brains in response to Aβ aggregation and do not display frank neuronal loss (Jucker 2010).”
Kane, M. D., Lipinski, W. J., Callahan, M. J., Bian, F., Durham, R. A., Schwarz, R. D., Roher, A. E., & Walker, L. C. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03606.2000 · Cited by 394 · cited 3×
“Characteristic PrP prions Aβ prions Reference(s) for Aβ Induction of protein aggregation in Tg mice expressing mutant precursor protein Yes Yes (Kane et al. 2000; Meyer-Luehmann et al. 2006) Induction of protein aggregation in Tg mice expressing wild-type precursor protein Yes Yes (Morales et al.…”
Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation
Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H., Yan, Z.-X., Roth, K., Aguzzi, A., Staufenbiel, M., Walker, L. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903200106 · Cited by 279 · cited 9×
“Although iatrogenic AD transmission is only one potential explanation for these observations, sterilization methods for surgical tools may need to be reconsidered, especially since Aβ seeds remain active once bound to stainless steel (Eisele et al. 2009).”
InfluentialSoluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition
Langer, F., Eisele, Y. S., Fritschi, S. K., Staufenbiel, M., Walker, L. C., & Jucker, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3088-11.2011 · Cited by 237 · cited 3×
“Treatment of Aβ prion preparations with proteinase K (PK) did not abolish their infectivity (Langer et al. 2011; Stöhr et al. 2012), implying that self-propagating Aβ aggregates are densely packed and likely large in size.”
Some Speculations about Prions, Amyloid, and Alzheimer's Disease
Prusiner, S. B. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403083101021 · Cited by 213 · cited 1×
“The molecular and pathological similarities between AD and the PrP prion diseases led to speculation that prions may feature in the pathogenesis of AD, and that, like CJD and kuru, AD may be transmissible to nonhuman primates (Prusiner 1984).”
Self-citationMaia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Bioluminescence imaging of Aβ deposition in bigenic mouse models of Alzheimer's disease
Watts, J. C., Giles, K., Grillo, S. K., Lemus, A., DeArmond, S. J., & Prusiner, S. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019034108 · Cited by 109 · cited 3×
“Characteristic PrP prions Aβ prions Reference(s) for Aβ Induction of protein aggregation in Tg mice expressing mutant precursor protein Yes Yes (Kane et al. 2000; Meyer-Luehmann et al. 2006) Induction of protein aggregation in Tg mice expressing wild-type precursor protein Yes Yes (Morales et al. 2012) Induction of pr…”
Self-citation
Cited by
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 185
“According to this hypothesis, the starting event in AD is the aggregation and subsequent deposition of the Aβ peptide in the brain [20,21], resulting in the hyperphosphorylation of tau into NFTs and, ultimately, the degeneration of neurons.”
BackgroundAlzheimer disease and the periodontal patient: New insights, connections, and therapies
Ryder, M. I., & Xenoudi, P. (2021) · Periodontology 2000 · doi:10.1111/prd.12389 · Cited by 55
The modulation of neuroinflammation by inducible nitric oxide synthase
Justo, A. F. O., & Suemoto, C. K. (2022) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-021-00663-x · Cited by 44
Metadata
- Authors
- Watts, J. C., & Prusiner, S. B.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-02-13
- Volume
- 8
- Issue
- 5
- Pages
- a023507
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2588650504
- Cited by
- 82
- References
- 32
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.